Table 1.
Cancer | GO Term | GeneSet | Description | Count | p-value | FDR |
---|---|---|---|---|---|---|
BRCA | BP | GO:0002250 | Adaptive immune response | 368 | 0 | 0 |
GO:0045088 | Regulation of innate immune response | 350 | 0 | 0 | ||
GO:0036230 | Granulocyte activation | 476 | 0 | 0 | ||
GO:0002446 | Neutrophil mediated immunity | 473 | 0 | 0 | ||
GO:0002694 | Regulation of leukocyte activation | 461 | 0 | 0 | ||
GO:0002764 | Immune response-regulating signaling pathway | 452 | 0 | 0 | ||
GO:0032615 | Interleukin-12 production | 53 | 0 | 0 | ||
GO:0032612 | Interleukin-1 production | 86 | 0 | 0 | ||
GO:0002449 | Lymphocyte mediated immunity | 229 | 0 | 0 | ||
GO:0042110 | T cell activation | 439 | 0 | 0 | ||
GO:0002683 | Negative regulation of immune system process | 392 | 0 | 0 | ||
GO:0050727 | Regulation of inflammatory response | 349 | 0 | 0 | ||
GO:0002697 | Regulation of immune effector process | 365 | 0 | 0 | ||
GO:0032635 | Interleukin-6 production | 120 | 0 | 0 | ||
CC | GO:0042611 | MHC protein complex | 19 | 0.006309 | 0.005403 | |
GO:0001772 | Immunological synapse | 32 | 0.002899 | 0.007356 | ||
MF | GO:0042287 | MHC protein binding | 24 | 0 | 0.003098 | |
GO:0019865 | Immunoglobulin binding | 22 | 0 | 0.003835 | ||
COAD | BP | GO:0002269 | Leukocyte activation involved in inflammatory response | 31 | 0 | 0.007515 |
GO:0032613 | Interleukin-10 production | 46 | 0 | 0.010735 | ||
GO:0032633 | Interleukin-4 production | 34 | 0 | 0.011836 | ||
GO:0042116 | Macrophage activation | 78 | 0 | 0.01362 | ||
GO:0032612 | Interleukin-1 production | 86 | 0 | 0.01409 | ||
GO:0071887 | Leukocyte apoptotic process | 103 | 0 | 0.014403 | ||
GO:0032615 | Interleukin-12 production | 53 | 0 | 0.014703 | ||
GO:0150076 | Neuroinflammatory response | 48 | 0 | 0.014859 | ||
GO:0071706 | Tumor necrosis factor superfamily cytokine production | 133 | 0 | 0.014925 | ||
CC | GO:0042611 | MHC protein complex | 19 | 0.008584 | 0.019271 | |
MF | GO:0019865 | Immunoglobulin binding | 22 | 0 | 0 | |
GO:0042287 | MHC protein binding | 24 | 0.006263 | 0.04006 | ||
LUAD | BP | GO:0045088 | Regulation of innate immune response | 125 | 0 | 0 |
GO:0042110 | T cell activation | 149 | 0 | 0 | ||
GO:0002694 | Regulation of leukocyte activation | 167 | 0 | 0 | ||
GO:0070661 | Leukocyte proliferation | 98 | 0 | 0 | ||
GO:0002250 | Adaptive immune response | 121 | 0 | 0.000551 | ||
GO:0002697 | Regulation of immune effector process | 129 | 0 | 0.00058 | ||
GO:0030101 | Natural killer cell activation | 24 | 0 | 0.000612 | ||
GO:0032635 | Interleukin-6 production | 43 | 0 | 0.000648 | ||
GO:0042116 | Macrophage activation | 28 | 0 | 0.000735 | ||
GO:0002446 | Neutrophil mediated immunity | 147 | 0 | 0.000735 | ||
GO:0002764 | Immune response-regulating signaling pathway | 159 | 0 | 0.000787 | ||
GO:0002285 | Lymphocyte activation involved in immune response | 53 | 0 | 0.000826 | ||
GO:0002449 | Lymphocyte mediated immunity | 85 | 0 | 0.000881 | ||
GO:0002440 | Production of molecular mediator of immune response | 65 | 0 | 0.001502 | ||
GO:0042113 | B cell activation | 66 | 0 | 0.002204 | ||
LUSC | BP | GO:0042116 | Macrophage activation | 78 | 0 | 0 |
GO:0032635 | Interleukin-6 production | 120 | 0 | 0 | ||
GO:0032612 | Interleukin-1 production | 86 | 0 | 0 | ||
GO:0002446 | Neutrophil mediated immunity | 472 | 0 | 0 | ||
GO:0050900 | Leukocyte migration | 394 | 0 | 0 | ||
GO:0002250 | Adaptive immune response | 363 | 0 | 0 | ||
GO:0032637 | Interleukin-8 production | 67 | 0 | 0 | ||
GO:0002764 | Immune response-regulating signaling pathway | 452 | 0 | 0 | ||
CC | GO:0042611 | MHC protein complex | 19 | 0 | 0.000887 | |
GO:0001772 | Immunological synapse | 32 | 0 | 0.001893 | ||
MF | GO:0019865 | Immunoglobulin binding | 22 | 0 | 0 | |
GO:0042287 | MHC protein binding | 24 | 0.002283 | 0.005568 | ||
STAD | BP | GO:0002446 | Neutrophil mediated immunity | 473 | 0 | 0 |
GO:0002764 | Immune response-regulating signaling pathway | 452 | 0 | 0 | ||
GO:0032612 | Interleukin-1 production | 86 | 0 | 0 | ||
GO:0002250 | Adaptive immune response | 368 | 0 | 0 | ||
GO:0032623 | Interleukin-2 production | 63 | 0 | 0 | ||
GO:0031349 | Positive regulation of defense response | 407 | 0 | 0 | ||
GO:0032635 | Interleukin-6 production | 120 | 0 | 0 | ||
GO:0006959 | Humoral immune response | 223 | 0 | 0 | ||
GO:0002697 | Regulation of immune effector process | 365 | 0 | 0 | ||
GO:0007159 | Leukocyte cell–cell adhesion | 310 | 0 | 0 | ||
GO:0002694 | Regulation of leukocyte activation | 461 | 0 | 0 | ||
GO:0002449 | Lymphocyte mediated immunity | 229 | 0 | 0 | ||
GO:0002285 | Lymphocyte activation involved in immune response | 167 | 0 | 0 | ||
CC | GO:0042611 | MHC protein complex | 19 | 0.009772 | 0.008677 | |
GO:0001772 | Immunological synapse | 32 | 0.003155 | 0.0107 | ||
MF | GO:0019865 | Immunoglobulin binding | 22 | 0 | 0 | |
GO:0042287 | MHC protein binding | 24 | 0.006079 | 0.008962 |
Significant GO terms correlated with immunology were demonstrated in the table.
BRCA breast invasive carcinoma, COAD colon adenocarcinoma, LUAD lung Adenocarcinoma, LUSC lung squamous cell carcinoma, STAD stomach adenocarcinoma, GO gene ontology, BP biological process, CC cellular component, MF molecular function.